Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CDC42 | P60953 | 1/20 | 0.57 |
| ▸ | RAC1 | P63000 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.51 |
| ▸ | TUBB | P07437 | 2/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490839 | 0.86 | TSHR (0.71) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL30127939 | 0.86 | TSHR (0.71) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL14032691 | 0.86 | ACHE (0.61) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL5122373 | 0.86 | ACHE (0.61) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL490776 | 0.86 | ACHE (0.61) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL28747725 | 0.85 | AKR1C3 (0.58) | AKR1C3AKR1C2TSHRBLMNPSR1 | |
| Hydrochloric Acid SCHEMBL3225395 | 0.84 | ACHE (0.59) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL31103530 | 0.84 | PTGS2 (0.53) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL503700 | 0.83 | NPSR1 (0.76) | TSHRBLMNPSR1TUBB4ATUBB | |
| SCHEMBL352960 | 0.83 | NPSR1 (0.76) | TSHRBLMNPSR1TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409974-B | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-12-21 | — | — | CN | claimed |
| CN-112409974-A | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-02-26 | — | — | CN | claimed |
| CN-117990868-A | Method for evaluating influence of yoghurt on flavone and phenolic acid in orange juice by adopting in-vitro model simulating gastrointestinal digestion | 上海交通大学医学院 | 2024-05-07 | — | — | CN | disclosed |
| CN-116535366-B | Thiazole compound and preparation method and application thereof | 广州医科大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-116535366-A | Thiazole compound and preparation method and application thereof | 广州医科大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| CN-112409974-B | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-12-21 | — | — | CN | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| CN-112409974-A | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-02-26 | — | — | CN | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | AKR1C3 334/4885AKR1C2 338/4885PTGS2 755/4885 |
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | AKR1C3 289/4885AKR1C2 266/4885PTGS2 320/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | AKR1C3 733/4885AKR1C2 1012/4885PTGS2 1873/4885 |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | AKR1C3 1058/4885AKR1C2 1323/4885PTGS2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.